8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                             CURRENT REPORT PURSUANT
                         TO SECTION 13 OR 15 (d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  March 16, 2005
                                                   --------------


                       SANGUI BIOTECH INTERNATIONAL, INC.
             (Exact name of Registrant as specified in its charter)

                                    Colorado
          (State or other jurisdiction of Incorporation or organization

      000-21271                                      84-1330732
 ----------------------                      -------------------------------
(Commission File Number)                   (I.R.S. Employer Identification No.)

                Alfred-Herrhausen-Str. 44, 58455 Witten, Germany
               (Address of principal executive offices) (Zip Code)

                              011-49-2302-915-204
              (Registrant's telephone number, including area code)

                                       N/A
          (Former name or former address, if changed since last report)

         Check the appropriate box below if the Form 8-K filing is intended to
Simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

     [ ] Written communications pursuant to Rule 425 under the Securities Act
     (17 CFR 230.425)

     [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
     CFR 240.14a-12)

     [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240-14d-2(b))

     [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

                                       1

                            Section 8 - Other Events

Item 8.01         Other Events


     On March 16, 2005, Sangui Biotech International, Inc. (Pink Sheets: SGBI)
issued a press release announcing that SanguiBioTech GmbH, of Witten, Germany, a
wholly-owned subsidiary of Sangui BioTech International, Inc., has sold an
initial quantity of it's anti-cellulite gel to a German cosmetics distributor at
a price of approximately $ 35,000.

     A copy of the press release is furnished as Exhibit 99.3 to this report.

     The information in this Current Report on Form 8-K, including the exhibit,
is furnished under "Item 8.01 Other Events" in accordance with SEC Release No.
33-8216. Furthermore, the information in this Current Report on Form 8-K,
including the exhibit, shall not be deemed to be incorporated by reference into
the filings of the Company under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended.


                                   SIGNATURES

         Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the Undersigned, thereunto duly authorized.

                                        Sangui Biotech International, Inc.
                                        (Registrant)


Date: March 16, 2005                    /S/ Wolfgang Barnikol
                                        ---------------------------------------
                                        By: Wolfgang Barnikol
                                        Its: President, CEO and CFO



                                       2

                                INDEX TO EXHIBITS


Exhibit Number                      Exhibit
         99.1                       Press Release dated March 16, 2005*

     * This exhibit is furnished to, but not filed with, the Commission by
     inclusion herein.

                                       3

EX-99

                                  Exhibit 99.1

                       Press Release dated March 16, 2005


Sangui sells first quantity of anti-cellulite gel


Witten, Germany, March 16, 2005 - SanguiBioTech GmbH sold an initial quantity of
it's anti-cellulite gel to a German cosmetics distributor at a price of
approximately $ 35,000. The distributor intends to offer the preparation in
German TV shop programmes under his own brand name. Sales are expected to
commence early/mid April.

Sangui's anti-cellulite gel obtained premium results in recent tests with
several groups of probands carried out by Dermatest, a renowned independent
cosmetics research institute headquartered in Muenster, Germany. Skin elasticity
improved over 40% in average in four weeks treatments and up to 61,5% in longer
term treatments.

SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech International,
Inc. (www.pinksheets.com: SGBI)


For more information please contact:

Joachim Fleing
Phone: +49 (160) 741 27 17
Fax: +49 (2302) 915 191
e-mail: fleing@sangui.de


Some of the statements contained in this news release discuss future
expectations, contain projections of results of operation or financial condition
or state other "forward-looking" information. These statements are subject to
known and unknown risks, uncertainties, and other factors that could cause the
actual results to differ materially from those contemplated by the statements.
The forward-looking information is based on various factors and is derived using
numerous assumptions. Important factors that may cause actual results to differ
from projections include, among many others, the ability of the Company to raise
sufficient capital to meet operating requirements. Words such as "anticipates,"
"expects," "intends," "plans," "believes," "seeks," "estimates," and variations
of such words and similar expressions are intended to identify such
forward-looking statements. Unless required by law, the Company undertakes no
obligation to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.